NASDAQ: MNPRMonopar Therapeutics Stock
$81.77+13.11 (+19.09%)
Updated Jun 23, 2026
MNPR Price
$81.77
Fair Value Price
$8.32
Market Cap
$547.78M
52 Week Low
$29.18
52 Week High
$105.00
P/E
-42.37x
P/B
4.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$10M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MNPR Overview
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNPR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNPR
Ranked#258 of 467
Ranked#258 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.25 | A | |
| $51.34 | A | |
| $2.17 | A |
Be the first to know about important MNPR news, forecast changes, insider trades & much more!
MNPR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNPR ($81.77) is overvalued by 882.51% relative to our estimate of its Fair Value price of $8.32 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MNPR ($81.77) is not significantly undervalued (882.51%) relative to our estimate of its Fair Value price of $8.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MNPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MNPR due diligence checks available for Premium users.
Valuation
MNPR fair value
Fair Value of MNPR stock based on Discounted Cash Flow (DCF)
Price
$81.77
Fair Value
$8.32
Overvalued by
882.51%
MNPR ($81.77) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MNPR ($81.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MNPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MNPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-42.37x
Industry
15.59x
Market
7.68x
MNPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.05x
Industry
5.15x
MNPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MNPR's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.9M
Profit Margin
0%
MNPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$138.0M
Liabilities
$2.6M
Debt to equity
0.02
MNPR's short-term assets ($137.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNPR's short-term assets ($137.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MNPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$5.6M
Financing
-$200.2k
MNPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNPR vs Biotech Stocks
Monopar Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.